Cytomel and Peak expiratory flow rate decreased - a phase IV clinical study of FDA data

Summary:

Peak expiratory flow rate decreased is reported only by a few people who take Cytomel.

The phase IV clinical study analyzes which people take Cytomel and have Peak expiratory flow rate decreased. It is created by eHealthMe based on reports of 6,191 people who have side effects while taking Cytomel from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Aug, 17, 2022

6,191 people reported to have side effects when taking Cytomel.
Among them, 3 people (0.05%) have Peak expiratory flow rate decreased.


What is Cytomel?

Cytomel has active ingredients of liothyronine sodium. It is often used in hypothyroidism. eHealthMe is studying from 6,484 Cytomel users for its effectiveness, alternative drugs and more.

What is Peak expiratory flow rate decreased?

Peak expiratory flow rate decreased is found to be associated with 259 drugs and 94 conditions by eHealthMe.

Number of Cytomel and Peak expiratory flow rate decreased reports submitted per year:

Could Cytomel cause Peak expiratory flow rate decreased?

Gender of people who have Peak expiratory flow rate decreased when taking Cytomel *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Peak expiratory flow rate decreased when taking Cytomel *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 100 %
  • 60+: 0.0 %

Common drugs people take besides Cytomel *:

  1. Ventolin: 3 people, 100.00%
  2. Vitamin D: 2 people, 66.67%
  3. Symbicort: 2 people, 66.67%
  4. Prednisone: 2 people, 66.67%
  5. Fish Oil: 2 people, 66.67%
  6. Calcium: 2 people, 66.67%
  7. Synthroid: 1 person, 33.33%
  8. Seebri: 1 person, 33.33%
  9. Ranitidine: 1 person, 33.33%
  10. Omega-3 Fatty Acids: 1 person, 33.33%

Common side effects people have besides Peak expiratory flow rate decreased *:

  1. Breathing Difficulty: 3 people, 100.00%
  2. Pneumonia: 2 people, 66.67%
  3. High Blood Pressure: 2 people, 66.67%
  4. Cough: 2 people, 66.67%
  5. Asthma: 2 people, 66.67%
  6. Abdominal Distension: 2 people, 66.67%
  7. Wheezing (a high-pitched whistling sound made while you breath): 1 person, 33.33%
  8. Sputum Retention: 1 person, 33.33%
  9. Productive Cough: 1 person, 33.33%
  10. Overdose: 1 person, 33.33%

Common conditions people have *:

  1. Asthma: 2 people, 66.67%
  2. Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you take Cytomel and have Peak expiratory flow rate decreased?

Check whether Peak expiratory flow rate decreased is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Peak expiratory flow rate decreased and when was it recovered:

Expand to all the drugs that have ingredients of liothyronine sodium:

Alternative drugs to, pros and cons of Cytomel:

Common Cytomel side effects:

Browse all side effects of Cytomel:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Peak expiratory flow rate decreased treatments and more:

COVID vaccines that are related to Peak expiratory flow rate decreased:

Common drugs associated with Peak expiratory flow rate decreased:

All the drugs that are associated with Peak expiratory flow rate decreased:

Common conditions associated with Peak expiratory flow rate decreased:

All the conditions that are associated with Peak expiratory flow rate decreased:

How the study uses the data?

The study uses data from the FDA. It is based on liothyronine sodium (the active ingredients of Cytomel) and Cytomel (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: